| Daratumumab-based treatment for immunoglobulin light-chain amyloidosis E Kastritis, G Palladini, MC Minnema, AD Wechalekar, A Jaccard, HC Lee, ... New England Journal of Medicine 385 (1), 46-58, 2021 | 376 | 2021 |
| Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA G Palladini, E Kastritis, MS Maurer, J Zonder, MC Minnema, ... Blood, The Journal of the American Society of Hematology 136 (1), 71-80, 2020 | 207 | 2020 |
| Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy G Jeyakumar, S Kim, N Bumma, C Landry, C Silski, S Suisham, B Dickow, ... Journal for immunotherapy of cancer 5, 1-8, 2017 | 88 | 2017 |
| Daratumumab proves safe and highly effective in AL amyloidosis. J Khouri, A Kin, B Thapa, FJ Reu, N Bumma, CJ Samaras, HD Liu, ... British Journal of Haematology 185 (2), 2019 | 57 | 2019 |
| Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of … PM Voorhees, DW Sborov, J Laubach, JL Kaufman, B Reeves, ... The Lancet Haematology 10 (10), e825-e837, 2023 | 40 | 2023 |
| Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (Pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis … JP Laubach, JL Kaufman, DW Sborov, B Reeves, C Rodriguez, A Chari, ... Blood 138, 79, 2021 | 37 | 2021 |
| Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific monoclonal antibody, in a phase 1/2 first-in-human study in … JA Zonder, J Richter, N Bumma, J Brayer, JE Hoffman, WI Bensinger, ... Blood 138, 160, 2021 | 35 | 2021 |
| LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. HC Lee, N Bumma, JR Richter, MV Dhodapkar, JE Hoffman, ... Journal of Clinical Oncology 41 (16_suppl), 8006-8006, 2023 | 34 | 2023 |
| Stem cell mobilization yields with daratumumab-and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and … S Chhabra, N Callander, NL Watts, LJ Costa, B Thapa, JL Kaufman, ... Transplantation and Cellular Therapy 29 (3), 174. e1-174. e10, 2023 | 32 | 2023 |
| Updated safety and efficacy of REGN5458, a BCMAxCD3 bispecific antibody, treatment for relapsed/refractory multiple myeloma: a phase 1/2 first-in-human study N Bumma, J Richter, J Brayer, JA Zonder, M Dhodapkar, MR Shah, ... Blood 140 (Supplement 1), 10140-10141, 2022 | 30 | 2022 |
| Reduction in absolute involved free light chain and difference between involved and uninvolved free light chain is associated with prolonged major organ deterioration … RL Comenzo, E Kastritis, G Palladini, MC Minnema, AD Wechalekar, ... Blood 136, 48-50, 2020 | 23 | 2020 |
| Analysis of transplant-eligible patients (Pts) who received frontline daratumumab (DARA)-Based quadruplet therapy for the treatment of newly diagnosed multiple myeloma (NDMM … N Callander, R Silbermann, JL Kaufman, KN Godby, JP Laubach, ... Blood 140 (Supplement 1), 10144-10147, 2022 | 20 | 2022 |
| Potential of NK cells in multiple Myeloma therapy AM Khan, S Devarakonda, N Bumma, M Chaudhry, DM Benson Jr Expert review of hematology 12 (6), 425-435, 2019 | 18 | 2019 |
| Daratumumab plus lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (Pts): final analysis of griffin … A Chari, JL Kaufman, JP Laubach, DW Sborov, B Reeves, C Rodriguez, ... Blood 140 (Supplement 1), 7278-7281, 2022 | 17 | 2022 |
| Effect of exposure to Agent Orange on the risk of monoclonal gammopathy and subsequent transformation to multiple myeloma: a single-center experience from the Veterans Affairs … N Bumma, M Nagasaka, G Hemingway, H Miyashita, T Chowdhury, S Kim, ... Clinical Lymphoma Myeloma and Leukemia 20 (5), 305-311, 2020 | 16 | 2020 |
| AL amyloidosis: the effect of fluorescent in situ hybridization abnormalities on organ involvement and survival M Ozga, Q Zhao, D Benson Jr, P Elder, N Williams, N Bumma, A Rosko, ... Cancer Medicine 10 (3), 965-973, 2021 | 15 | 2021 |
| Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia N Bumma, N Papadantonakis, AS Advani Future Oncology 11 (12), 1729-1739, 2015 | 13 | 2015 |
| Effect of early post-transplantation tacrolimus concentration on the risk of acute graft-versus-host disease in allogenic stem cell transplantation N Sharma, Q Zhao, B Ni, P Elder, M Puto, DM Benson, A Rosko, ... Cancers 13 (4), 613, 2021 | 12 | 2021 |
| Improvement in post-autologous stem cell transplant survival of multiple myeloma patients: a long-term institutional experience J Nunnelee, F Cottini, Q Zhao, MS Faisal, P Elder, A Rosko, N Bumma, ... Cancers 14 (9), 2277, 2022 | 11 | 2022 |
| Daratumumab in patients with bortezomib-refractory proliferative glomerulonephritis with monoclonal immunoglobulin deposits S Almaani, SV Parikh, AA Satoskar, N Bumma, BH Rovin, N Sharma, ... Kidney International Reports 6 (8), 2203-2206, 2021 | 11 | 2021 |
